(Q34330211)

1 August 2017

title

Treating multiple sclerosis with monoclonal antibodies: a 2013 update (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

Annika Deiß

1

1 reference

1 August 2017

Isabel Brecht

series ordinal

2

1 reference

1 August 2017

Axel Haarmann

series ordinal

3

1 reference

1 August 2017

Mathias Buttmann

series ordinal

4

1 reference

1 August 2017

language of work or name

1 reference

1 March 2013

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 August 2017

published in

1 reference

1 August 2017

volume

13

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

313-335

1 reference

Treating multiple sclerosis with monoclonal antibodies: a 2010 update.

1 August 2017

cites work

1 reference

Treating multiple sclerosis with monoclonal antibodies

21 January 2018

1 reference

Treating multiple sclerosis with natalizumab

21 January 2018

1 reference

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

21 January 2018

1 reference

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab

21 January 2018

1 reference

Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

Treatment of multiple sclerosis with anti-CD20 antibodies

21 January 2018

1 reference

Development of anti-CD20 therapy for multiple sclerosis.

21 January 2018

1 reference

Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

21 January 2018

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

21 January 2018

1 reference

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?

21 January 2018

1 reference

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

21 January 2018

1 reference

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

21 January 2018

1 reference

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

21 January 2018

1 reference

Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders

21 January 2018

1 reference

Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort

21 January 2018

1 reference

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

21 January 2018

1 reference

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod

21 January 2018

1 reference

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

21 January 2018

1 reference

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

21 January 2018

1 reference

The role of natalizumab in hematopoietic stem cell mobilization

21 January 2018

1 reference

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors

21 January 2018

1 reference

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism

21 January 2018

1 reference

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

21 January 2018

1 reference

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis

21 January 2018

1 reference

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

21 January 2018

1 reference

Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis

21 January 2018

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

21 January 2018

1 reference

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

21 January 2018

1 reference

Can we get rid of neutralizing antibodies against interferon-β?

21 January 2018

1 reference

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

The evidence for a role of B cells in multiple sclerosis

21 January 2018

1 reference

Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.

21 January 2018

1 reference

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

21 January 2018

1 reference

The late adverse events of rituximab therapy--rare but there!

21 January 2018

1 reference

The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis.

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in autoimmune diseases

21 January 2018

1 reference

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease

21 January 2018

1 reference

IL-17: a new actor in IFN-driven systemic autoimmune diseases

21 January 2018

1 reference

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

21 January 2018

1 reference

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

21 January 2018

1 reference

Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies

21 January 2018

1 reference

Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis

21 January 2018

1 reference

Human endogenous retroviruses in multiple sclerosis: potential for novel neuro-pharmacological research

21 January 2018

1 reference

Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination

21 January 2018

1 reference

LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex

21 January 2018

1 reference

LINGO-1 negatively regulates myelination by oligodendrocytes

21 January 2018

1 reference

Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models

21 January 2018

1 reference

Neutralization of LINGO-1 during in vitro differentiation of neural stem cells results in proliferation of immature neurons

21 January 2018

1 reference

Colony-stimulating factors in inflammation and autoimmunity.

21 January 2018

1 reference

CD19: a promising B cell target for rheumatoid arthritis

21 January 2018

1 reference

Fingolimod for multiple sclerosis

21 January 2018

1 reference

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision

21 January 2018

1 reference

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.13.17

1 reference

1 August 2017

1 reference